Vnitr Lek 2020, 66(7):409-413 | DOI: 10.36290/vnl.2020.119

Current diagnosis and therapy in sarcoidosis

Martina Šterclová
Pneumologická klinika 2. LF UK a FN Motol, Praha
Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

Sarcoidosis is a disorder of unknown etiology, that may affect any organ in human body, most often lungs and lymph nodes. New diagnostic guidelines and new treatment recommendations were recently published. Since differential diagnosis of sarcoidosis is broad, diagnostic algorithm has to be complex. Diagnosis needs to be confirmed before initiation of any any treatment regimen - it is a severe mistake to start treatment before confirmation of diagnosis (histologic pattern of epitheloid non necrotising granuloma, exclusion of other possible causes of granulomatous diseases, exclusive situations mentioned in the article body). Not every patient with sarcoidosis needs pharmacologic treatment. Treatment decision should involve extent of involvement, risk of damage of affected organs and patient symptoms. While in patients with Löfgren syndrome both histologic verification and systemic corticotherapy is not needed (systemic corticotherapy should be avoided), pharmacologic treatment is necessary in patients with myocardial involvement.

Keywords: sarcoidosis, diagnosis, therapy, granuloma.

Published: November 3, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šterclová M. Current diagnosis and therapy in sarcoidosis. Vnitr Lek. 2020;66(7):409-413. doi: 10.36290/vnl.2020.119.
Download citation

References

  1. Culver DA, Judson MA. New advances in the management of pulmonary sarcoidosis. BMJ 2019; 367: 15553. Go to original source... Go to PubMed...
  2. Kolek V, Losťáková V, Vašáková M, Žurková M. Sarkoidóza (Doporučený postup diagnostiky, terapie a sledování vývoje onemocnění). Dostupné na: www.pneumologie.cz/guidelines, navštíveno: 8. 8. 2020.
  3. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. AJRCCM 2020; 8: e26-e51. Go to original source... Go to PubMed...
  4. Jeny F, Bernaudin JF, Cohen Aubart F, et al. Diagnosis issues in sarcoidosis. Respir Med and Res 2020; 77: 37-45. Go to original source... Go to PubMed...
  5. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961; 2: 1165-1172. Go to original source... Go to PubMed...
  6. Statement on sarcoidosis. Joint statement of American Thoracici Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). AJRCCM 1999; 160: 736-755.
  7. Kidd DP. Neurosarcoidosis: clinical manifestations, investigation and treatment. Pract Neurol 2020; 20: 199-2121. Go to original source... Go to PubMed...
  8. Roth D, Kadoglou N, Leeflang M, et al. Diagnostic accuracy of cardiac MRI, FDG‑PET, and myocardial biopsy for the diagnosis of cardiac sarcoidosis: a protocol for a systematic review and meta‑analysis. Diagnostic and Prognostic Research 2020; 4: 5. Go to original source... Go to PubMed...
  9. Baughman RP, Scholand MB, Rahaghi FF. Clinical phenotyping: role in treatemnt decisions in sarcoidosis. Eur Respir Rev 2020; 29: 190145. Go to original source... Go to PubMed...
  10. Jammal TE, Jamilloux Y, Gerfraud‑Valentin M, et al. Refractory sarcoidosis: A Review. Therapeutics and Clinical Risk Management 2020; 16: 323-345. Go to original source... Go to PubMed...
  11. Vis R, van de Garde EWM, Grutters J, Korenromp IHE. The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review. Eur Respir Rev 2020; 29: 190057. Go to original source... Go to PubMed...
  12. Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 56-64.
  13. Kirkil G, Lower EE, Baughman RP. Predictors of mortality in pulmonary sarcoidosis. Chest 2018; 153: 105-113. Go to original source... Go to PubMed...
  14. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The realtionship of relapse to corticosteroid therapy. Chest 1997; 111: 623-631. Go to original source... Go to PubMed...
  15. McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficiancy of short‑course, low‑dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010; 339: 1-4. Go to original source... Go to PubMed...
  16. Martin K, Bentaberry F, Dumoulin C, et al. Peripherall neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf 2007; 16: 74-78. Go to original source... Go to PubMed...
  17. Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experienca‑based recommendations for use of TNF‑alpha inhibitors in sarcoidosis. Carcoidosis Vasc Diffuse Lung Dis 2014; 31: 91-107.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.